Down Syndrome Alzheimer Disease
Mostrando 1-12 de 53 artigos, teses e dissertações.
-
1. The validity and reliability of the CAMDEX-DS for assessing dementia in adults with Down syndrome in Brazil
Objective: Alzheimer’s disease occurs at a higher prevalence and an earlier age in individuals with Down syndrome (DS) than typically developing individuals. However, diagnosing dementia in individuals with intellectual disability remains a challenge due to pre-existing cognitive deficits. The aim of this study was to investigate the validity and reliabil
Braz. J. Psychiatry.. Publicado em: 22/10/2018
-
2. Combined association of Presenilin-1 and Apolipoprotein E polymorphisms with maternal meiosis II error in Down syndrome births
Abstract Alzheimer's disease and Down syndrome often exhibit close association and predictively share common genetic risk-factors. Presenilin-1 (PSEN-1) and Apolipoprotein E (APOE) genes are associated with early and late onset of Alzheimer's disease, respectively. Presenilin −1 is involved in faithful chromosomal segregation. A higher frequency of the APO
Genet. Mol. Biol.. Publicado em: 31/07/2017
-
3. Alterações sistêmicas e comportamentais de interesse odontológico em pacientes com síndrome de Down / Dental implications of systemic and behavior alterations in Downs syndrome patients
Downs syndrome (DS) is the most common genetic disorder and it is caused by the trissomy of 21 chromosome. It is characterized by mental retardation, physical alterations and several systemic co morbidities. The aim of this study was to evaluate behavior and systemic alterations with dental implications in DS patients and discuss the dental management of the
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 30/03/2011
-
4. Prevenção primária da síndrome de Down e da doença de Alzheimer: Investigação de polimorfismos gênicos acentuadores da deposição cerebral de beta amilóide
O desenvolvimento de mudanças neuropatológicas características da doença de Alzheimer (DA) nos portadores de síndrome de Down (SD) a partir dos 40 anos de idade e a alta taxa de indivíduos com SD em famílias nas quais a DA está presente sugerem uma susceptibilidade comum entre as duas doenças. Além disso, mulheres jovens (<35 anos na concepção) q
Publicado em: 2009
-
5. Investigação da atividade e da concentração da anidrase carbonica eritrocitaria em pacientes com quadro clinico sugestivo da doença de Alzheimer
Carbonic anhydrase, (CA) (EC 4.2.1.1) is a zinc-containing mettalloenzym, wich central function is the hydration of carbon dioxide and the dehydration of carbonic acid, and íts naturalsubstrate is carbon dioxide. So far, in human species only seven isozymes of carbonic Inhydrase have been identified. wich differ from each other concerning their molecular st
Publicado em: 1992
-
6. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Interleukin 1, an immune response-generated cytokine that stimulates astrocyte proliferation and reactivity (astrogliosis), was present in up to 30 times as many glial cells in tissue sections of brain from patients with Down syndrome and Alzheimer disease compared with age-matched control subjects. Most interleukin 1-immunoreactive glia in Down syndrome and
-
7. Olfactory function in young adolescents with Down's syndrome.
Decreased ability to smell is present in adults with Down's syndrome, many of whom are known to have brain pathology analogous to that seen in Alzheimer's disease. Because olfactory loss is well documented in Alzheimer's disease, the question arises whether young adolescents with Down's syndrome, who have no clear Alzheimer's disease-like neuropathology, als
-
8. Isolated senile plaque cores in Alzheimer's disease and Down's syndrome show differences in morphology.
Frontal and temporal cortical tissue from the brains of elderly cases of Down's syndrome was used to make preparations of neuronal cell bodies containing senile plaque cores. Polarisation microscopy revealed normal "classical" plaque cores, and also a high proportion of unusual "amorphous" plaque cores which we have not seen in Alzheimer's disease. These two
-
9. The substantia nigra and ventral tegmental area in Alzheimer's disease and Down's syndrome.
Degenerative changes in the substantia nigra and ventral tegmental area were investigated in 104 cases of Alzheimer's disease and 13 cases of Down's syndrome. Frequencies of tangles in three groups of patients with Alzheimer's disease were 86%, 44% and 46% (54% overall) respectively. About half of those with tangles, but no Lewy bodies, had excess nigral cel
-
10. Reexpression of a developmentally regulated antigen in Down syndrome and Alzheimer disease.
ALZ-50 is a monoclonal antibody that recognizes a protein of apparent molecular mass 68 kilodaltons (A68). The protein is present in the brains of patients with Alzheimer disease but is not detectable in normal adult brain tissue. We now report that ALZ-50-reactive neurons are found in normal fetal and neonatal human brain and in brain tissue from neonatal i
-
11. Amyloid plaque core protein in Alzheimer disease and Down syndrome.
We have purified and characterized the cerebral amyloid protein that forms the plaque core in Alzheimer disease and in aged individuals with Down syndrome. The protein consists of multimeric aggregates of a polypeptide of about 40 residues (4 kDa). The amino acid composition, molecular mass, and NH2-terminal sequence of this amyloid protein are almost identi
-
12. Dopaminergic neurotransmitter systems in Alzheimer's disease and in Down's syndrome at middle age.
In 15 patients with Alzheimer's disease and in 10 with Down's syndrome at middle age, there was severe atrophy, neurofibrillary degeneration and loss of pigmented dopaminergic nerve cells from ventral tegmental area (A10) whereas nerve cells in neighbouring substantia nigra (A9) were much less affected in all three respects. It is suggested that these findin